We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

129 hedge funds and large institutions have $2.4B invested in Loxo Oncology, Inc in 2017 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 49 increasing their positions, 24 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,075% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 4

267% more funds holding in top 10

Funds holding in top 10: 311 (+8)

113% more capital invested

Capital invested by funds: $1.12B → $2.4B (+$1.27B)

104% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 24

50% more funds holding

Funds holding: 86129 (+43)

63% less call options, than puts

Call options by funds: $2.09M | Put options by funds: $5.7M

Holders
129
Holders Change
+43
Holders Change %
+50%
% of All Funds
3.21%
Holding in Top 10
11
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+266.67%
% of All Funds
0.27%
New
47
Increased
49
Reduced
24
Closed
4
Calls
$2.09M
Puts
$5.7M
Net Calls
-$3.62M
Net Calls Change
-$3.62M

LOXO Hedge Fund Activity: Q2 2017 in Review

129 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q2 2017, worth a combined $2.4B — up 113% from $1.12B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new LOXO positions and 4 closed out — a net gain of 43 holders — while 49 added to existing stakes and 24 trimmed.

The largest buyer was OppenheimerFunds, opening a new position worth an estimated $36.5M. The largest seller was Victory Capital Management, cutting an estimated $29.5M.

  • 129 institutional investors held Loxo Oncology, Inc (LOXO) as of Q2 2017, up from 86 in Q1 2017.
  • Funds reported $2.4B of Loxo Oncology, Inc stock for Q2 2017, up 113% quarter-over-quarter.
  • 47 funds opened new Loxo Oncology, Inc positions in Q2 2017 and 4 closed out, a net change of +43 holders.
  • The largest Loxo Oncology, Inc buyer in Q2 2017 was OppenheimerFunds, an estimated $36.5M added.
  • The largest Loxo Oncology, Inc seller in Q2 2017 was Victory Capital Management, an estimated $29.5M sold.

Based on aggregated 13F filings for Q2 2017.